|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.04.26 - 16:09
|
Orchid Island Capital to Announce First Quarter 2026 Results (GlobeNewswire EN)
|
|
|
VERO BEACH, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced that it will release results for the first quarter of 2026 following the close of trading on the New York Stock Exchange on Thursday, April 23, 2026....
|
|
|
|
|
|
|
07.04.26 - 16:03
|
Altus Group releases its 2025 Sustainability Report (GlobeNewswire EN)
|
|
|
TORONTO, April 07, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group” or “the Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, today published its 2025 Sustainability Report, outlining how the Company advanced its sustainability initiatives and delivered measurable progress throughout the year....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.04.26 - 15:21
|
NurExone Biologic′s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization (GlobeNewswire EN)
|
|
|
TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) and BioXtek Inc. (“BioXtek”) today announced that Exo-Top Inc., NurExone's wholly owned U.S. subsidiary, (“Exo-Top” and together, with BioXtek, the “Parties”) has entered into a non-binding letter of intent (the “LOI”) with BioXtek, a Florida-based company, to explore a strategic partnership in the field of regenerative therapies for exosome manufacturing and commercialization....
|
|